RxDoctor Payments Data

Wilantha Silva, APRN

Family · Augusta, GANPI 1043698574

Payments from drug & device makers

$939in general payments, 2019–2025

Across 23 payments — averaging $40.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$173
  • Otsuka America Pharmaceutical, Inc.$137
  • AstraZeneca$125
  • Astellas Pharma US Inc$120
  • GSK$111
  • Mylan Specialty L.p.$41
  • plus $232 from 10 others

What the payments were for

  • Food & beverage$939100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$939 in reported general payments places this provider in the 65th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$5,399
Medicare patients
40
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide134$201,117
Tresiba Flextouch U-200Insulin Degludec68$65,510
MounjaroTirzepatide38$52,300
JardianceEmpagliflozin22$29,019
TrulicityDulaglutide16$26,774
FarxigaDapagliflozin Propanediol19$20,154
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog27$19,160
Soliqua 100-33Insulin Glargine/Lixisenatide11$16,505
Fiasp FlextouchInsulin Aspart (Niacinamide)16$10,829
Tresiba Flextouch U-100Insulin Degludec11$6,011
Novolog FlexpenInsulin Aspart19$4,212
Nano 2nd Gen Pen NeedlePen Needle, Diabetic28$2,609
LantusInsulin Glargine,hum.Rec.Anlog12$2,468
Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm16$2,319
HumalogInsulin Lispro11$1,941

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$34$29,01922 claims
AstraZenecaFarxiga$125$20,15419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,258 family providers in Georgia.

Other family in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →